Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
FYECPueZNA8WzpRD
Listen
